Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy

References

• Rives S, Maude SL, Hiramatsu H, Baruchel A, Bader P, Bittencourt H, Buechner J, Laetsch T, De Moerloose B, Qayed M, et al. Tisagenlecleucel in pediatric and young adult patients (Pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-All): final analyses from the eliana study. HemaSphere. 2022;6:1–8. doi:10.1097/01.HS9.0000843344.19780.98.
   Google Scholar
• Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403–15. doi:10.1016/S1470-2045(21)00375-2.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Dickinson M, Lopez JM, Kolstad A, Butler JP, Ghosh M, Popplewell LL, Chavez J, Bachy E, Kato K, et al. Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the Elara trial. American Society of Hematology (ASH) Annual Meeting and Exposition New Orleans, Louisiana; 2022.
   Google Scholar
• Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020;16:136–44. doi:10.1016/j.omtm.2019.11.018.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. doi:10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• John S, Pulsipher MA, Moskop A, Z-H H, Phillips CL, Hall EM, Margossian SP, Nikiforow S, Martin PL, Oshrine B, et al. Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 2021;138:428.
   Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8. doi:10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Den Neste E V, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51:51–7. doi:10.1038/bmt.2015.213.
   PubMed Web of Science ®Google Scholar
• Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational national lymphoCare study. Br J Haematol. 2019;184:660–3. doi:10.1111/bjh.15149.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Frigault M, Heim M, Foley SR, Hill BT, Ho CM, Jacobson CA, Jaglowski S, Locke FL, Ram R, et al. Real-world outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-hodgkin’s lymphoma (aBNHL) treated with commercial tisagenlecleucel: subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 2022;140:1584–7.
   Web of Science ®Google Scholar
• Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022;28:669–76. doi:10.1016/j.jtct.2022.07.011.
   PubMedGoogle Scholar
• Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386:629–39. doi:10.1056/NEJMoa2116596.
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871–83. doi:10.1182/bloodadvances.2020001837.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Longo DL, Wilson WH. CAR T-cell therapy for large B-cell lymphoma - who, when, and how? N Engl J Med. 2022;386:692–6. doi:10.1056/NEJMe2118899.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139:2306–15. doi:10.1182/blood.2021014738.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–30. doi:10.1182/blood-2016-04-703751.
   PubMed Web of Science ®Google Scholar
• Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4. doi:10.1186/s40364-018-0116-0.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor–Modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–18. doi:10.1056/NEJMoa1215134.
   PubMed Web of Science ®Google Scholar
• Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:35. doi:10.1186/s13045-018-0571-y.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. doi:10.1182/blood-2014-05-552729.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38. doi:10.1016/j.bbmt.2018.12.758.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4:1432–9. doi:10.1182/bloodadvances.2019001304.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4:1440–7. doi:10.1182/bloodadvances.2019001305.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978–92. doi:10.1200/JCO.21.01992.
   PubMed Web of Science ®Google Scholar
• Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012;20:246–9. doi:10.1038/mt.2011.288.
   PubMed Web of Science ®Google Scholar
• Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101. doi:10.1016/j.omtm.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Pacaud L, Waldron E, Tam CS, Jager U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4:560–72. doi:10.1182/bloodadvances.2019000525.
   PubMed Web of Science ®Google Scholar
• Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24:6175–84. doi:10.1158/1078-0432.CCR-18-0758.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503–9. doi:10.1038/s41586-021-04390-6.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Mueller KT, Yanik GA, Tam CS, Rives S, McGuirk JP, Pulsipher MA, Boyer MW, Jaeger U, Baruchel A, et al. Evaluation of in vivo CAR transgene levels in relapsed/refractory pediatric and young adult ALL and adult DLBCL tisagenlecleucel-treated patients. Blood. 2018;132:899. doi:10.1182/blood-2018-99-116385.
   Web of Science ®Google Scholar
• Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414–24. doi:10.1182/bloodadvances.2020003092.
   PubMed Web of Science ®Google Scholar
• Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, et al. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023;7:541–548. doi:10.1182/bloodadvances.2022007246.
   PubMed Web of Science ®Google Scholar
• Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano J-A, Moskop A, Margossian SP, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945–55. doi:10.1200/JCO.20.03585.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54. doi:10.1056/NEJMoa1708566.
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3:66–81. doi:10.1158/2643-3230.BCD-21-0095.
   PubMedGoogle Scholar
• Flinn IW, Jaeger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Lu D, Zhu X, et al. A first-in-human study of YTB323, a novel, autologous CD19-directed CAR-T cell therapy manufactured using the novel T-Charge TM platform, for the treatment of patients (Pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Blood. 2021;138:740. doi:10.1182/blood-2021-146268.
   Google Scholar
• Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022;28:404 e1–e6 . doi:10.1016/j.jtct.2022.03.021.
   PubMedGoogle Scholar
• Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leuk Lymphoma. 2022;63:2052–62. doi:10.1080/10428194.2022.2060503.
   PubMed Web of Science ®Google Scholar
• Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value. Institute for Clinical and Economic Review; 2018 Mar 23.
   Google Scholar
• Hao Y, Eldjerou LK, Yang H, Qi C, Globe D. Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States. Blood. 2017;130:609.
   Google Scholar
• Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson AQL, Davis KL, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36:3192–202. doi:10.1200/JCO.2018.79.0642.
   PubMed Web of Science ®Google Scholar
• Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P, Ramsey SD. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21:1238–45. doi:10.1080/13696998.2018.1529674.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172:1161–8. doi:10.1001/jamapediatrics.2018.2530.
   PubMed Web of Science ®Google Scholar
• Baumgardner J, Everson K, Brauer M, Zhang J, Hao Y, Liu J, Lakdawalla DN. CAR-T therapy displays favorable gains in health outcomes and competitive cost-effectiveness when compared with past innovative cancer treatments. Blood. 2018;132:322. doi:10.1182/blood-2018-99-116763.
   Web of Science ®Google Scholar
• Snider JT, Brauer M, Batt K, Karaca-Mandic P, Zhang J, Goldman DP. The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: what are consequences of treatment delays? J Clin Oncol. 2018;36:10529. doi:10.1200/JCO.2018.36.15_suppl.10529.
   Web of Science ®Google Scholar
• Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al. 5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023. doi:10.1182/blood.2022018893.
   PubMedGoogle Scholar